- Home
- ANNX vs GFR Comparison
ANNX vs GFR Comparison
Compare ANNX & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- GFR
- Stock Information
- Founded
- ANNX 2011
- GFR 2018
- Country
- ANNX United States
- GFR Canada
- Employees
- ANNX N/A
- GFR N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- GFR
- Sector
- ANNX Health Care
- GFR
- Exchange
- ANNX Nasdaq
- GFR Nasdaq
- Market Cap
- ANNX 334.1M
- GFR 330.9M
- IPO Year
- ANNX 2020
- GFR N/A
- Fundamental
- Price
- ANNX $3.00
- GFR $4.83
- Analyst Decision
- ANNX Strong Buy
- GFR
- Analyst Count
- ANNX 4
- GFR 0
- Target Price
- ANNX $13.00
- GFR N/A
- AVG Volume (30 Days)
- ANNX 2.1M
- GFR 33.5K
- Earning Date
- ANNX 11-13-2025
- GFR 11-03-2025
- Dividend Yield
- ANNX N/A
- GFR N/A
- EPS Growth
- ANNX N/A
- GFR N/A
- EPS
- ANNX N/A
- GFR 2.05
- Revenue
- ANNX N/A
- GFR $516,308,125.00
- Revenue This Year
- ANNX N/A
- GFR N/A
- Revenue Next Year
- ANNX N/A
- GFR $32.45
- P/E Ratio
- ANNX N/A
- GFR $2.28
- Revenue Growth
- ANNX N/A
- GFR N/A
- 52 Week Low
- ANNX $1.29
- GFR $3.81
- 52 Week High
- ANNX $7.74
- GFR $7.95
- Technical
- Relative Strength Index (RSI)
- ANNX 51.42
- GFR 53.62
- Support Level
- ANNX $2.87
- GFR $4.46
- Resistance Level
- ANNX $3.36
- GFR $4.71
- Average True Range (ATR)
- ANNX 0.21
- GFR 0.20
- MACD
- ANNX -0.03
- GFR 0.01
- Stochastic Oscillator
- ANNX 25.24
- GFR 59.84
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.